

USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket No. 8654/2222		Serial No. 10/790,943	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				Applicant(s): Wilson & Siim			
				Filing Date: March 2, 2004		Group: 1614	
U.S. PATENT DOCUMENTS							
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation YES NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)							
cm	1	Showalter & Hollis; "Potential Antitumor Agents. 61. Structure-Activity Relationships for In Vivo Colon 38 Activity Among Disubstituted 9-Oxo-9H-xanthene-4-acetic acids"; 1991; <u>Chemtracts: Org. Chem.</u> 4(2): 168-171.					
	2	Shoemaker, et al.; "Pleiotropic Resistance and Drug Development"; 1986; <u>Progress Clin. Biol. Res.</u> ; 223: 143-149.					
	3	Van der Auwera, et al.; "Conformational Features of Four Model Tripeptides having Piv-Pro-MeXaa-Nme <sub>2</sub> Sequences"; 1988; <u>Bull. Soc. Chim. Belg.</u> ; 97(3): 199-207.					
	4	Ching & Baguley; "The Anti-Tumour and Immune-Modulatory Activities of Flavone Acetic and Xanthone Acetic Acids"; 1990; <u>N.P. Das (ed.), flavanoids in Biology and Medicine III. Proceedings of the 3<sup>rd</sup> International Symposium on Flavonoids in Biology and Medicine, Singapore; National University of Singapore</u> ; 381-391.					
	5	Rustin, et al.; "Impact on Tumour Perfusion Measured by Dynamic Magnetic Resonance Imaging (MRI), in the Phase 1 Trial of 5,6-dimethylxanthene-4-acetic Acid (DMXAA)"; <u>Proc. 10th NCI-EORTC Symp. New Drugs</u> ; 1998; 10: 126. <i>abstract is illegible</i>					
cm	6	Bibby, et al.; "Reduction of Tumor Blood Flow by Flavone Acetic Acid: A Possible Component of Therapy"; 1989; <u>J. Natl. Cancer Inst.</u> ; 81: 216-220.					
	7	Zhou, et al.; "Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthene-4-acetic (DMXAA) by human liver microsomes"; 2001; <u>Br. J. Clin. Pharmacol.</u> ; 52: 129-136.					
	8.	Rewcastle, et al.; "Potential Antitumor Agents. 61. Structure-Activity Relationships for In Vivo Colon 38 Activity Among Disubstituted 9-Oxo-9H-xanthene-4-acetic acids"; 1991; <u>J. Med. Chem.</u> ; 34: 217-222.					
EXAMINER				DATE CONSIDERED			
cm				477-06			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							
**Copies of references not provided at the time of this submission.							

USPTO Form 1449 U.S. Department of Commerce  
Patent and Trademark Office

## INFORMATION DISCLOSURE STATEMENT

Attorney Docket No.

8654/2222

Serial No.

10/790,943

Applicant(s): Wilson et al.

Filing Date: March 2, 2004

Group: 1614

## U.S. PATENT DOCUMENTS

Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)

## FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Publication Date	Country	Class	Subclass	Translation	
						YES	NO

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

cm	A.	Hill, et al., "Anti-Vascular Approaches to Solid Tumour Therapy: Evaluation of Vinblastine and Flavone Acetic Acid", International Journal of Cancer (1995), V. 63, No. 1, Pages 119-123.
cm	B.	Wilson; "Combination of the Antivascular Agent DMXAA with Radiation and Chemotherapy"; 2000; <u>International Journal of Radiation Oncology, Biology and Physics</u> ; 46(3): 706.

EXAMINER

cm

DATE CONSIDERED

4-17-06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*\*Copies of references not provided at the time of this submission.